ACER Call for Evidence

on the conditions for the application of FDA UIOLI pursuant to paragraph 2.2.3.1 a) - d) of the CMP Guidelines

(“congestion indicators”)

PC_2016_G_01

Fields marked with * are mandatory.

Background & objective

According to paragraph 2.2.1.2 of the Commission Guidelines on Congestion Management Procedures[1] (hereafter, the ‘CMP GL’) the Agency for the Cooperation of Energy Regulators (‘the Agency’) has to publish a yearly monitoring report on contractual congestion[2] at interconnection points (‘IPs’), taking into consideration, to the extent possible, capacity trading on the secondary market and the use of interruptible capacity.

Paragraph 2.2.3.1 specifies the conditions[3] under which a specific CMP - i.e. the Firm day-ahead Use-It-Or-Lose-It mechanism (‘FDA UIOLI’) - is to be applied. The Agency has used each of these conditions as an indicator for contractual congestion (“congestion indicators”). Accordingly, in the ACER Congestion Reports[4], the Agency had identified contractual congestion at those IP sides where at least one of the conditions of the “congestion indicators” (conditions 2.2.3.1 a) – d)) was fulfilled.

Some stakeholders (including TSOs, NRAs and network users) have expressed doubts on whether the “congestion indicators” are able to correctly identify actual situations of contractual congestion. Some stakeholders suggested also to include other elements or criteria in the
decision-making process on whether an IP side is to be considered “contractually congested” and therefore would require the application of the FDA UIOLI.

To investigate these issues, **the Agency is inviting stakeholders to formulate concrete suggestions to improve the “congestion indicators”. The aim is to check if it is possible to improve the existing “congestion indicators” and/or define criteria to be used by the Agency in its congestion analysis.** Such criteria would have to:

- appropriately reflect / describe circumstances that identify persistent existence of contractual congestions at IP sides,
- be objective and replicable,
- be based on data which is or will have to be made available at least to the Agency in a timely manner,
- and be applicable - with reasonable efforts - across the EU.

Please note that, by launching this exercise in the form of a survey, the Agency does not commit to propose amendments[5] to the existing provisions related to the “congestion indicators”. Whether the Agency will do so depends to a large extent on the proposals which will be received, the support these proposals enjoy among stakeholders, and the Agency’s assessment of whether such proposals would be an improvement compared to the current formulation.

Next to the above mentioned main topic, the questionnaire covers a number of additional issues which were raised in the recommendations section of the Agency’s latest Congestion Report.


[3] i.e. points a) – d) of paragraph 2.2.3.1


**Respondent identification**

E-mail address

[REDACTED]
Question 0 – Respondent identification: Please indicate your name, e-mail address, company/organisation, type of stakeholder (organisation) you are representing and whether or not you agree that your answer is published.

Name and Surname (not to be published)

*Company/organisation

Interconnector (UK) Limited

* Please let us know the type of stakeholder (organisation) you are representing

- Network user
- TSO
- Producer
- NRA
- EU or international organisation
- National association
- Government
- Other (please specify)

* Do you agree that your answer will be published?

- Yes
- No

Survey questions

Question 1: Do you consider the existing “congestion indicators” (conditions 2.2.3.1 a) – d) of CMP GL) appropriate and sufficient to determine the existence of contractual congestion (as defined in Regulation 715/2009) at IP sides? In case not, what alternative indicators would you suggest? Please be as concrete as possible with your proposal and provide a justification.

- Yes
- No
- Neutral / I don’t know

Reasons and alternative formulation:

The congestion indicators do not provide sufficient information to distinguish between scenarios such as:

i) where there is an actual problem with contractual congestion as capacity is owned but not being used when spreads indicate that there is
demand for capacity in the market; and
ii) contractual congestion but no actual issue as interested parties can access the asset either through the secondary market or by using short-term capacity made available through the OS&BB process or Interruptible Capacity.

Just because capacity has not been offered by the TSO does not mean that there is unmet demand.

A more appropriate solution would be for the congestion indicators to act as a trigger for TSOs to provide further information to enable a proper assessment of the situation. This could include information on capacity trading on the secondary market, use of Interruptible Capacity and the availability of capacity through other CMP mechanisms such as OS&BB.

The current drafting of conditions 2.2.3.1a)-d) is not clear legally and this should be addressed.

Question 2: Do you think that the “congestion indicators” should further specify how to take into consideration capacity trading on the secondary market and the use of interruptible capacity[6]? If so, please indicate how this should be done. Please give reasons for your answer.

[6] In its past annual congestion reports, the Agency applied the current “congestion indicators”, but also reported on other elements, such as on the extent of secondary capacity trading, the application of CMPs, the offer and bookings of interruptible capacities, actual interruptions of interruptible capacities, the occurrence of unsuccessful requests, a congestion comparison with previous years, and on further specific market conditions at IP sides found contractually congested by applying the “congestion indicators”.

☑ Yes
☐ No
☐ Neutral / I don’t know

Reasons and specification:

See above answer to Question 1.
Question 3: In cases of contractual congestion, do you consider FDA UIOLI to be an appropriate mechanism to mitigate the effects of the identified contractual congestion? If not, what alternative or additional measure would you suggest to address the congestion and why?

Your view:

FDA UIOLI obliges the TSO to offer a short-term product in response to a long-term issue. Restricting the renomination rights of Shippers reduces the value of the capacity and affects the flexibility that a Shipper believed they were purchasing. OS&BB and LT UIOLI mechanisms would seem to be sufficient responses. Requiring the TSO to implement a further mechanism increases costs on all parties.
Question 4: In its latest congestion report[7], the Agency recommends clarifying the scope of criterion d) of paragraph 2.2.3.1 of the CMP GL to align it with the other congestion criteria. The current wording of criterion d) considers an IP side not congested, if capacity for at least one month was offered out of the 12 months in the preceding year’s rolling monthly auction procedures. The Agency would propose amending the text so that all 12 monthly products should be offered at an IP in order for it not to be considered as contractually congested, as there is no way to test “demand exceeding offer” in auction regimes if no such product is offered. (Also, no quota applies for monthly products.)


Do you support this recommendation? Please provide reasons.

☐ Yes
☐ No
☑ Neutral / I don’t know

Reasons:

Neutral as long as the congestion indicators are only a trigger to initiate a proper analysis of whether there is actually an issue with accessing capacity.
Question 5: With respect to paragraph 2.2.1 of the CMP GL, the Agency recommends in its latest congestion report that the Commission clarifies

a) until when the Agency shall produce congestion reports (or under which conditions the reports are no longer required);

b) an implementation period for the FDA UIOLI mechanism, if congestion is identified at IP sides only after 1 July 2016.

Please provide your views on these 2 issues, including concrete suggestions and reasons.

Your view on a):

No opinion.

What would be an appropriate implementation period for b):

Sufficient time must be allowed for implementation taking into consideration potential changes to contractual arrangements and the IT systems of both the TSO and Shippers.
**Question 6:** Do you think the CMP GL should set out an implementation process for the FDA UIOLI, specifying when (under which measurable conditions) to terminate the application of FDA UIOLI?

- [ ] Yes
- [ ] No
- [x] Neutral / I don’t know

**Your view:**

NRAs should be able to terminate the requirement to apply FDA UIOLI immediately if the problem ceases to exist.

---

**Question 7:** In its latest congestion report, the Agency also suggests to consider extending the scope of “contractual congestion” to the day-ahead timeframe between hubs (requiring the Agency to assess auction premia and the non-offer of firm DA products at a cross-zonal level), which could then also result in the mandatory application of the FDA UIOLI mechanism at IPs/VIPs/IP sides between the corresponding market areas, to promote a short-term gas market price convergence.
Do you support this suggestion? Please provide reasons.

☐ Yes
☒ No
☐ Neutral / I don’t know

Reasons:

If the other CMP mechanisms are applied it should not be necessary to require TSOs to implement FDA UIOLI.

Question 8: In your view, should the Agency assess in more depth[8] the possible existence of physical congestion at IPs? Please provide your view, reasons and concrete suggestions for further possible indicators.

[8] To date, the Agency has used the occurrence of actual interruptions of nominated interruptible capacity as an indicator for the (temporary) existence of physical congestion.

☐ Yes
☒ No
☐ Neutral / I don’t know
Your view:

Not required.

Question 9: Do you have any other suggestions on how to improve the CMP GL?

See suggestion in response to question 1.
Contact

✉ cmpsurvey@acer.europa.eu